Ratings Jiangsu Nhwa Pharmaceutical Co., LTD

Equities

002262

CNE100000CG8

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
25.06 ^CNY	-0.75%		+0.20%	-7.60%

Apr. 25	Jiangsu Nhwa Pharmaceutical Co., LTD Approves Cash Dividend for 2023	CI
Apr. 19	Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

The company's enterprise value to sales, at 3.73 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JIANGSU NHWA PHARMACEUTICAL CO., LTD	-7.60%	3.53B	-
ELI LILLY AND COMPANY	+32.95%	700B	C+
NOVO NORDISK A/S	+26.51%	569B	B
JOHNSON & JOHNSON	-4.97%	358B	C+
MERCK & CO., INC.	+18.83%	330B	B-
ABBVIE INC.	+3.54%	287B	C+
ASTRAZENECA PLC	+15.70%	236B	B+
NOVARTIS AG	+6.68%	202B	B-
ROCHE HOLDING AG	-9.08%	197B	A+
AMGEN INC.	+6.70%	161B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes